Profile data is unavailable for this security.
About the company
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain management, gynecology, and dermatology. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its Anti-diabetic products include Gliclazide 80 mg, Tablets, Gliclazide 30 mg, Tablets, Glimepiride 1, 2, 3, 4 mg, Tablets, and others. Its dermatologic therapy products include Macrotor, Ahaglow S Facewash, Fungicide Lotion, Hairjoy 2%, New Dewsoft Cream, Lookbrite 20GMS, Cortaz NC, Dermanex, and others. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim.
- Revenue in INR (TTM)127.42bn
- Net income in INR22.72bn
- Incorporated1972
- Employees16.11k
- LocationTorrent Pharmaceuticals LtdTorrent House, Off. Ashram RoadAHMEDABAD 380059IndiaIND
- Phone+91 7 926599000
- Fax+91 7 926582100
- Websitehttps://www.torrentpharma.com/
Mergers & acquisitions
| Acquired company | TORNTPHARM:NSI since announced | Transaction value |
|---|---|---|
| J B Chemicals & Pharmaceuticals Ltd | 26.17% | 697.10m |
| J B Chemicals & Pharmaceuticals Ltd | 26.17% | 1.48bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mankind Pharma Ltd | 138.42bn | 17.75bn | 860.00bn | 27.00k | 48.51 | -- | 32.12 | 6.21 | 42.95 | 43.05 | 334.94 | -- | -- | -- | -- | 5,126,748.00 | -- | 14.93 | -- | 19.39 | 71.39 | 67.59 | 13.00 | 17.70 | -- | 3.64 | -- | 0.00 | 18.98 | 15.79 | 3.90 | 14.03 | 18.41 | -- |
| Zydus Lifesciences Ltd | 260.89bn | 49.38bn | 916.13bn | 27.92k | 18.55 | -- | 15.09 | 3.51 | 49.08 | 49.08 | 259.31 | -- | -- | -- | -- | 9,345,309.00 | -- | 10.92 | -- | 16.35 | 73.12 | 63.12 | 18.91 | 16.73 | -- | -- | -- | 17.81 | 18.90 | 10.27 | 17.96 | 30.92 | 13.63 | 25.74 |
| Lupin Ltd | 261.51bn | 46.45bn | 1.02tn | 19.98k | 20.45 | -- | 16.95 | 3.88 | 108.62 | 108.62 | 603.92 | -- | -- | -- | -- | 13,088,990.00 | -- | 4.53 | -- | 7.16 | 72.62 | 59.70 | 17.86 | 5.95 | -- | 183.80 | -- | 29.13 | 13.48 | 8.11 | 71.41 | -- | 20.11 | 14.87 |
| Dr Reddy's Laboratories Ltd | 346.82bn | 55.68bn | 1.06tn | 26.94k | 19.00 | -- | 14.13 | 3.05 | 66.81 | 66.81 | 416.15 | -- | -- | -- | -- | 12,871,960.00 | -- | 12.15 | -- | 16.94 | 65.76 | 66.18 | 15.92 | 15.81 | -- | 19.79 | -- | 14.69 | 16.54 | 13.26 | 1.38 | 22.84 | 41.26 | 9.86 |
| Cipla Ltd | 283.51bn | 45.46bn | 1.10tn | 30.31k | 24.11 | -- | 19.68 | 3.86 | 56.26 | 56.26 | 350.81 | -- | -- | -- | -- | 9,352,779.00 | -- | 11.89 | -- | 14.49 | 66.53 | 59.55 | 16.03 | 14.74 | -- | 96.40 | -- | 22.40 | 6.88 | 9.97 | 27.93 | 27.80 | 9.14 | 34.08 |
| Torrent Pharmaceuticals Ltd | 127.42bn | 22.72bn | 1.44tn | 16.11k | 63.49 | -- | 46.76 | 11.32 | 67.12 | 67.12 | 376.38 | -- | -- | -- | -- | 7,910,902.00 | -- | 9.54 | -- | 14.72 | 75.64 | 72.56 | 17.83 | 14.14 | -- | 16.34 | -- | 61.09 | 7.35 | 7.72 | 15.39 | 14.48 | 8.51 | 30.36 |
| Divi's Laboratories Ltd | 103.14bn | 24.79bn | 1.63tn | 18.30k | 65.81 | -- | 55.74 | 15.83 | 93.45 | 93.45 | 388.82 | -- | -- | -- | -- | 5,636,066.00 | -- | 15.81 | -- | 17.33 | 61.65 | 55.90 | 24.04 | 25.82 | -- | -- | -- | 35.19 | 19.31 | 11.65 | 36.94 | 9.74 | 3.98 | 13.40 |
| Holder | Shares | % Held |
|---|---|---|
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Dec 2025 | 4.92m | 1.45% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 4.11m | 1.21% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 4.02m | 1.19% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 3.54m | 1.05% |
| Goldman Sachs Asset Management LPas of 06 Feb 2026 | 3.09m | 0.91% |
| Polar Capital LLPas of 31 Dec 2025 | 2.50m | 0.74% |
| Axis Asset Management Co. Ltd.as of 31 Jan 2026 | 2.23m | 0.66% |
| Templeton Asset Management Ltd.as of 31 Dec 2025 | 2.20m | 0.65% |
| ICICI Prudential Life Insurance Co. Ltd. (Invt Port)as of 31 Jan 2026 | 1.86m | 0.55% |
| UTI Pension Fund Ltd.as of 30 Jan 2026 | 1.84m | 0.54% |
